person · Reporting owner
Siedhoff John Christopher
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sanara MedTech Inc.WNDM · Entity 5880 | Director | February 20, 2015 | April 06, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sanara MedTech Inc.
Report date February 20, 2015 · Filed April 06, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,150,000 |
Ending reported balance
After 2017-02-27 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2015-02-20 · Conversion · Acquired 750,000 · Balance 7,000,000 F1: The Series D Preferred Stock was convertible on a 1,000-for-1 basis, into shares of the issuer's common stock, upon the issuer's charter being amended to increase the number of authorized shares of common stock from 100,000,000 to 250,000,000. The issuer's charter was amended to reflect such increase in the number of authorized shares of common stock effective February 20, 2015. Row 2 · 2017-02-27 · Grant · Acquired 150,000 · Balance 7,150,000 |
| Series D Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2015-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2015-02-20 · Conversion · Disposed 750 · Balance 0 F1: The Series D Preferred Stock was convertible on a 1,000-for-1 basis, into shares of the issuer's common stock, upon the issuer's charter being amended to increase the number of authorized shares of common stock from 100,000,000 to 250,000,000. The issuer's charter was amended to reflect such increase in the number of authorized shares of common stock effective February 20, 2015. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series D Preferred Stock was convertible on a 1,000-for-1 basis, into shares of the issuer's common stock, upon the issuer's charter being amended to increase the number of authorized shares of common stock from 100,000,000 to 250,000,000. The issuer's charter was amended to reflect such increase in the number of authorized shares of common stock effective February 20, 2015.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2017 Filed Apr 6, 2017 00:14 UTC | Sanara MedTech Inc. WNDM · Entity 5880 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001385213-17-000004 · primary_doc.xml · nonDerivative · entry 2 Siedhoff John Christopher · CIK 0001385213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,150,000 Read SEC document |
| February 20, 2015 Filed Apr 6, 2017 00:14 UTC | Sanara MedTech Inc. WNDM · Entity 5880 | ConversionSeries D Preferred Stock · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001385213-17-000004 · primary_doc.xml · derivative · entry 3 Siedhoff John Christopher · CIK 0001385213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series D Preferred Stock was convertible on a 1,000-for-1 basis, into shares of the issuer's common stock, upon the issuer's charter being amended to increase the number of authorized shares of common stock from 100,000,000 to 250,000,000. The issuer's charter was amended to reflect such increase in the number of authorized shares of common stock effective February 20, 2015. F1 · derivative.exercise_date: The Series D Preferred Stock was convertible on a 1,000-for-1 basis, into shares of the issuer's common stock, upon the issuer's charter being amended to increase the number of authorized shares of common stock from 100,000,000 to 250,000,000. The issuer's charter was amended to reflect such increase in the number of authorized shares of common stock effective February 20, 2015. F1 · derivative.expiration_date: The Series D Preferred Stock was convertible on a 1,000-for-1 basis, into shares of the issuer's common stock, upon the issuer's charter being amended to increase the number of authorized shares of common stock from 100,000,000 to 250,000,000. The issuer's charter was amended to reflect such increase in the number of authorized shares of common stock effective February 20, 2015. Read SEC document |
| February 20, 2015 Filed Apr 6, 2017 00:14 UTC | Sanara MedTech Inc. WNDM · Entity 5880 | ConversionCommon Stock | 750,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001385213-17-000004 · primary_doc.xml · nonDerivative · entry 1 Siedhoff John Christopher · CIK 0001385213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series D Preferred Stock was convertible on a 1,000-for-1 basis, into shares of the issuer's common stock, upon the issuer's charter being amended to increase the number of authorized shares of common stock from 100,000,000 to 250,000,000. The issuer's charter was amended to reflect such increase in the number of authorized shares of common stock effective February 20, 2015. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.